So Many HCV “Guidelines”: Can’t We Wait Till the Dust Has Settled?
It was clear from the outset that the new roster of HCV drugs would change the playing field. Gilead’s NS5B polymerase inhibitor sofosbuvir and J&J’s NS3/4A protease inhibitor simeprevir have already revolutionized the treatment paradigm, pushing telaprevir and boceprevir, the Continue reading So Many HCV “Guidelines”: Can’t We Wait Till the Dust Has Settled?